Monopar Therapeutics News

Latest Monopar Therapeutics Stock News & MNPR Headlines

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

4 days ago | globenewswire.com

Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast

3 months ago | defenseworld.net

Monopar Appoints Jeffrey D. Kent, M.D.

3 months ago | globenewswire.com

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

3 months ago | globenewswire.com

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

5 months ago | zacks.com

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

5 months ago | globenewswire.com

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

6 months ago | globenewswire.com

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

6 months ago | globenewswire.com

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

7 months ago | globenewswire.com

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

7 months ago | globenewswire.com

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

MNPR

Monopar Therapeutics

$ 72.00

-0.94%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated 2 days ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Monopar Therapeutics News

Latest Monopar Therapeutics Stock News & MNPR Headlines

Download App

People Also Watch

Explore our Tools